Location of Repository

Use of Schistosoma mansoni calreticulin, a highly immunogenic parasite antigen, in diagnosis of and vaccination against schistosomiasis

By Bahaa El-Deen Wadea Ramadan El-Aswad


Due to copyright restrictions the published article (http://dx.doi.org/10.1016/j.imbio.2010.06.014) has been removed from the appendix of the electronic version of this thesis. The unabridged version can be consulted, on request, at the University of Leicester’s David Wilson Library.Ten sub-fragments (N-, P-, C-, NS-, NP-, NPC-, S-, SP-, SPC- and PC-domains) of recombinant S. mansoni calreticulin (SM-CRT), a highly immunogenic antigen, were expressed and purified. A cDNA library of adult S. mansoni was used as a template to amplify the coding sequences of these fragments which were expressed in bacterial expression system using the vector pRSETB. \ud SM-CRT sub-fragments (except those with N-terminal domain) were shown to bind calcium using “Stains-all” stain or interact with 45Ca2. With the exception of the P-domain, SM-CRT sub-fragments bound and inhibited C1q-dependent haemolysis in vitro. \ud In S. mansoni infected mice, specific antibodies against the carboxy-terminal part of SM-CRT appeared 46 days p.i., while antibodies against the N-terminal part of SM-CRT were detectable at 59 days p.i.. Cercarial Transformation Fluid (CTF) and Solube Egg Antigens (SEA) specific antibodies were detectable at day 12 p.i.. Use for diagnosis of S. mansoni in humans, CTF and SEA showed 89.7% sensitivity, while the PC-domain of SM-CRT showed sensitivity of 71.1% (the highest SM-CRT sub-fragment sensitivity). When testing the cross-reactivity with sera drawn from patients with other diseases, SM-CRT N-domain showed the lowest degree of cross-reactivity. Analysing non-endemic controls, a specificity >95% was shown for all of the antigens used. When using endemic controls, SM-CRT N-domain revealed the highest degree of specificity (94.7%), while SEA revealed 26.3% specificity and CTF showed 68.4% specificity. \ud BALB/c mice immunised with recombinant SM-CRT achieved a 49.9% (P >0.05) reduction in Schistosoma adult worm numbers (on exposure to S. mansoni cercariae), comparing to the non-immunised mice. The eggs numbers in the liver decreased by 41.8% in the immunised mouse group with a non-significant statistical difference. The immunised mice responded to SM-CRT immunisation by producing specific IgG1 and IgG2a, reflecting a Th1/Th2 with a predominance of Th2 immune response profile

Publisher: University of Leicester
Year: 2010
DOI identifier: 10.1016/j.imbio.2010.06.014)
OAI identifier: oai:lra.le.ac.uk:2381/9961

Suggested articles



  1. (1991). A 14-kDa Schistosoma mansoni polypeptide is homologous to a gene family of fatty acid binding proteins.
  2. (2001). A calreticulin-like molecule from the human hookworm Necator americanus interacts with C1q and the cytoplasmic signalling domains of some integrins.
  3. (2008). A century of schistosomiasis research.
  4. A comparative proteomic study of the underdeveloped and developed Schistosoma mansoni egg and its contents: The miracidium, hatch fluid and secrtions.
  5. (1997). A comparison of humoral responses to Schistosoma haematobium in areas with low and high levels of infection.
  6. (1999). A hookworm allergen which strongly resembles calreticulin.
  7. (1990). A human Ro/SS-A autoantigen is the homologue of calreticulin and is highly homologous with onchocercal RAL-1 antigen and an aplysia "memory molecule".
  8. (1974). A microplate method of enzymelinked immunosorbent assay and its application to malaria.
  9. (1976). A modification of the formol-ether concentration technique for increased sensitivity in detecting Schistosoma mansoni eggs.
  10. (2004). A national survey of the prevalence of schistosomiasis and soil transmitted helminths in Malawi.
  11. (1955). A new concentration
  12. (2006). A new PCR-based approach for the specific amplification of DNA from different Schistosoma species applicable to human urine samples.
  13. (1991). A new procedure for the separation of protein Z, prothrombin fragment 1.2 and calreticulin from human plasma.
  14. (1991). A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen
  15. (2002). A novel and sensitive method to monitor helminth infections by faecal sampling.
  16. (2003). A peptide derived from the parasite receptor, complement C2 receptor inhibitor trispanning, suppresses immune complex-mediated inflammation in mice.
  17. (1968). A quantitative post-mortem study of Schistosomiasis mansoni in man.
  18. (1997). A role for granulomatous inflammation in the transmission of infectious disease: schistosomiasis and tuberculosis.
  19. (2000). A Schistosoma mansoni 62-kDa band is identified as an irradiated vaccine T-cell antigen and characterized as calreticulin.
  20. (1985). A Schistosoma mansoni surface glycoprotein cross-reactive with a T1 antigen of Fasciola hepatica.
  21. (2000). A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2.
  22. (1972). A simple device for quantitative stool thicksmear technique in Schistosomiasis mansoni.
  23. (1994). A simple technique to pretreat urine and serum samples for quantitation of schistosome circulating anodic and cathodic antigen.
  24. (2003). acid-binding protein. Molecular, functioanl, and immunoprotection analysis.
  25. (1991). Acquired immunity and epidemiology of Schistosoma haematobium.
  26. (1976). Acquisition of human blood group antigens by Schistosoma mansoni.
  27. (1978). Acquisition of murine major histocompatibility complex gene products by schistosomula of Schistosoma mansoni.
  28. (1995). Acute human schistosomiasis mansoni.
  29. (1997). Acute schistosomiasis mansoni in the baboon Papio anubis gives rise to goblet-cell hyperplasia and villus atrophy that are modulated by an irradiated cercarial vaccine.
  30. (1993). Acute schistosomiasis: clinical, diagnostic and therapeutic features.
  31. (1998). Adjuvant is the major parameter influencing the isotype profiles generated during immunization with a protein antigen, the Schistosoma mansoni Sm28-GST.
  32. (1999). Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response.
  33. (1981). An analysis of allergy, immunoglobulin E, and diagnostic skin tests in schistosomiasis.
  34. (2005). an endemic area of Burkina Faso: performance of several immunological tests with different parasite antigens.
  35. (1997). An enzyme-linked immunosorbent assay using Schistosoma mansoni purified egg antigen for the diagnosis of schistosomiasis in Saudi Arabia.
  36. (2009). An evaluation of urine-CCA strip test and fingerprick blood SEAELISA for detection of urinary schistosomiasis in schoolchildren in Zanzibar.
  37. (1980). An examination of the skin phase of schistosome migration using a hamster cheek pouch preparation.
  38. (1991). An immunogenetically defined and immunodominant Trypanosoma cruzi antigen.
  39. (2005). An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis.
  40. (1992). Analysis of antikeyhole limpet haemocyanin antibody in Brazilians supports its use for the diagnosis of acute schistosomiasis mansoni.
  41. (1997). Analysis of granuloma formation in double cytokine-deficient mice reveals a central role for IL-10 in polarizing both T helper cell 1-and T helper cell 2-type cytokine responses in vivo.
  42. (2000). Analysis of the effects of treatment of human Schistosoma mansoni Davies,
  43. (1997). Analysis of the immune response elicited by a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite Schistosoma mansoni.
  44. (1995). Analysis of worm burden variation in human Schistosoma mansoni infections by determination of serum levels of circulating anodic antigen and circulating cathodic antigen.
  45. (1954). Anti-egg precipitins in the serum of humans infected with Schistosoma mansoni.
  46. (1997). Anti-gliadin antibodies in patients with celiac disease cross-react with enterocytes and human calreticulin.
  47. (1990). Antibody isotype responses to the Schistosoma mansoni schistosomulum in the CBA/N mouse induced by different stages of the parasite life cycle.
  48. (1991). Antigenic cross-reactivity between Necator americanus and Ascaris lumbricoides in a community in Papua New Guinea infected predominantly with hookworm.
  49. (1995). Antigens derived from lung-stage larvae of Schistosoma mansoni are efficient stimulators of proliferation and gamma interferon secretion by lymphocytes from mice vaccinated with attenuated larvae.
  50. (1996). Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults.
  51. (2004). Application of health promotion theories and models for environmental health. Health Educ Behav,
  52. (2007). Assay for trypanosome infection. International Patent Application WO2007/023316
  53. (1997). Assessment of cure by detection of circulating antigens in serum and urine, following schistosomiasis mass treatment in two villages of the Office du Niger,
  54. (2004). Association of type 2 cytokines with hepatic fibrosis in human Schistosoma mansoni infection.
  55. (1998). B cell sensitization to helminthic infection develops in utero in humans.
  56. (1998). B cells directly tolerize CD8(+) T cells.
  57. (1994). Bench aids for the diagnosis of intestinal parasites. World Health Organization;.
  58. (2002). Blueprint for schistosomiasis vaccine development.
  59. (2003). By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation.
  60. (2001). C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells.
  61. (1998). C1q and systemic lupus erythematosus.
  62. (1999). Ca2+ regulation of interactions between endoplasmic reticulum chaperones.
  63. (1990). Calcium binding proteins in schistosomes.
  64. (1996). Calreticulin binds hYRNA and the 52-kDa polypeptide component of the Ro/SS-A ribonucleoprotein autoantigen.
  65. (2003). Calreticulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies.
  66. Calreticulin in cardiac development and pathology.
  67. (2001). Calreticulin Is a receptor for nuclear export.
  68. (1999). Calreticulin is essential for cardiac development.
  69. Calreticulin modulates cell adhesiveness via regulation of vinculin expression.
  70. (1993). Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases.
  71. (2002). Calreticulin-like molecule in trophozoites of Entamoeba histolytica HM1:IMSS (Swissprot: accession P83003).
  72. (2005). Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum.
  73. (2009). Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum.
  74. (1995). Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries.
  75. (1994). Calreticulin: from
  76. (1994). Calreticulin: not just another calciumbinding protein.
  77. (1999). Calreticulin: one protein, one gene, many functions.
  78. (2000). CD4+ T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-gamma and tumour necrosis factor-alpha in response to the recombinant 14KDA Schistosoma mansoni fatty acid-binding protein.
  79. (1995). Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading.
  80. (2005). Cellular functions of endoplasmic reticulum chaperones calreticulin, calnexin, and ERp57.
  81. (1986). Cercariae to liver worms: development and migration in the mamamalian host.
  82. (2000). Changes in endoplasmic Chapter 8 Refrences reticulum luminal environment affect cell sensitivity to apoptosis.
  83. (1993). Characterization of a C3 receptor on the envelope of Schistosoma mansoni.
  84. (2005). Characterization of Haemonchus contortus calreticulin suggests its role in feeding and immune evasion by the parasite.
  85. (1979). Class specific antibodies and fluorescent staining patterns in acute and chronic forms of schistosomiasis mansoni.
  86. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
  87. (2002). Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni.
  88. (1996). Clinical, parasitological and immunological features of canal cleaners hyper-exposed to Schistosoma mansoni in the Sudan.
  89. (1993). Cloning and sequencing of the gene encoding Schistosoma mansoni calreticulin.
  90. (1995). Cloning of a Schistosoma japonicum gene encoding an antigen with homology to calreticulin.
  91. (2006). Co-administration of plasmid expressing
  92. (1987). Collaborative study on antigens for immunodiagnosis of Schistosoma japonicum infection.
  93. (1982). Collaborative study on antigens for immunodiagnosis of schistosomiasis.
  94. (1995). Collagen synthesis by human liver (myo)fibroblasts in culture: evidence for a regulatory role of
  95. (2003). Collections and ficolins: humoral lectins of the innate immune defense.
  96. (1987). Community water-contact patterns and the transmission of Schistosoma haematobium in the highveld region of Zimbabwe.
  97. (1991). Comparative analysis between the circumoval precipitin test and ELISA with raw antigens for the diagnosis of schistosomiasis in Venezuela.
  98. (1995). Comparison of antibody isotype responses to Schistosoma mansoni antigens by infected and putative resistant individuals living in an endemic area.
  99. (1985). Comparison of four schistosome excretory-secretory antigens: phenol sulfuric test active peak, cathodic circulating antigen, gut-associated proteoglycan, and circulating anodic antigen.
  100. (1995). Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein.
  101. (1991). Comparison of Th1- and Th2-associated immune reactivities stimulated by single versus multiple vaccination of mice with irradiated Schistosoma mansoni cercariae.
  102. (2007). Comparison of the Kato-Katz technique, hatching test and indirect hemagglutination assay (IHA) for the diagnosis of Schistosoma japonicum infection in China.
  103. (2000). Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia.
  104. (2002). Complement C2 receptor inhibitor trispanning and the beta-chain of C4 share a binding site for complement C2.
  105. (1989). Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes.
  106. (1992). Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass.
  107. (1990). Control of morbidity due to Schistosoma haematobium on Pemba Island: egg excretion and hematuria as indicators of infection.
  108. (1994). Covalent structure of bovine brain calreticulin.
  109. (2004). Current status and future prospects for a vaccine against schistosomiasis.
  110. (2008). Current status of vaccines for schistosomiasis.
  111. (1997). Cytokine regulation of human immune response to Schistosoma mansoni: analysis of the role of IL-4, IL-5 and IL-10 on peripheral blood mononuclear cell responses.
  112. (1996). Day-to-day egg count fluctuation in Schistosoma mansoni infection and its operational implications.
  113. (1997). Day-to-day variation of egg output and schistosome circulating antigens in urine of Schistosoma haematobium-infected school children from Gabon and follow-up after chemotherapy.
  114. (2000). Defining a schistosomiasis vaccination strategy - is it really
  115. (1921). den Nachweis der schistosomum mansoni-Eir im stuhl.Archiv fur Schiffs und Trpenhygiene,
  116. (2005). Dendritic cells activated with products released by schistosome larvae drive Th2-type immune responses, which can be inhibited by manipulation of CD40 costimulation.
  117. (2000). Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo.
  118. (1998). Detection and quantification of soluble egg antigen in urine of Schistosoma haematobium-infected children from Kenya.
  119. (1995). Detection of anti-Schistosoma antibodies in oral fluids.
  120. (1984). Detection of calcium binding proteins by 45Ca autoradiography on nitrocellulose membrane after sodium dodecyl sulfate gel electrophoresis.
  121. (1995). Detection of excretory-secretory circulating antigens in sheep infected with Fasciola hepatica and with Schistosoma mansoni and F.
  122. (2005). Detection of Schistosoma mansoni membrane antigens by immunoblot analysis of sera of patients from lowtransmission areas.
  123. (2005). Development and evaluation of a Western blot kit for diagnosis of schistosomiasis.
  124. (1986). Development and optimization of the FAST-ELISA for detecting antibodies to Schistosoma mansoni.
  125. (2010). Development of a new assay for the diagnosis of schistosomiasis, using cercarial antigens.
  126. (2003). Development of a rapid, sensitive, dye immunoassay for schistosomiasis diagnosis: a colloidal dye immunofiltration assay.
  127. (1995). Development of a vaccine strategy against human and bovine schistosomiasis. Background and update.
  128. (2000). Development of an immunoenzymatic assay for the detection of human antibodies against Trypanosoma cruzi calreticulin, an immunodominant antigen.
  129. (1986). Development of circulating antigen assay for rapid detection of acute schistosomiasis.
  130. (1997). Diagnosing schistosomiasis.
  131. (2004). Diagnosis of schistosomiasis by reagent strip test for detection of circulating cathodic antigen.
  132. (1998). Diagnosis of schistosomiasis: antibody detection, with notes on parasitological and antigen detection methods.
  133. (1989). Different T helper cell subsets elicited in mice utilising two different adjuvant vehicles: the role of endogenous IL-1 in proliferative responses.
  134. (1999). Dot enzyme-linked immunosorbent assay (dot-ELISA) for schistosomiasis diagnosis using dacron as solid-phase.
  135. (1992). DOT-dye-immunoassay for the diagnosis of schistosomiasis mansoni.
  136. (1995). DR4Dw4/DR53 molecules contain a peptide from the autoantigen calreticulin.
  137. (1990). Early antibody responses in human schistosomiasis.
  138. (2006). Early detection of Schistosoma mansoni infection by touchdown PCR in a mouse model.
  139. (1987). Early diagnosis of Schistosoma mansoni in mice using assays directed against cercarial antigens isolated by hydrophobic chromatography.
  140. (2008). Echinococcus granulosus calreticulin: molecular characterization and hydatid cyst localization.
  141. (1997). Effect of praziquantel and oxamniquine treatment on human isotype Chapter 8 Refrences responses to Schistosoma mansoni: elevated IgE to adult worm.
  142. (1981). Effect of Schistosoma mansoni infections on challenge infections with Fasciola hepatica in mice.
  143. (2003). Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert,
  144. (2005). Efficacy of an enzyme-linked immunosorbent assay as a diagnostic tool for schistosomiasis mansoni in individuals with low worm burden. Mem.Inst.Oswaldo Cruz,
  145. (1997). Efficacy of an enzyme-linked immunosorbent assay in the diagnosis of and serologic distinction between acute and chronic Schistosoma mansoni infection.
  146. (1998). Efficacy of praziquantel against Schistosoma mansoni in northern Senegal.
  147. (1985). Egg count variability and sensitivity of a thin smear technique for the diagnosis of Schistosoma mansoni.
  148. (1991). Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni.
  149. (1999). Egg laying is delayed but worm
  150. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
  151. (1994). Elevated expression of Th1 cytokines and nitric oxide synthase in the lungs of vaccinated mice after challenge infection with Schistosoma mansoni.
  152. (1996). Elevated proliferation and interleukin-4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection.
  153. (1996). Enhancement of Schistosoma mansoni infectivity by intradermal injections of larval extracts: a putative role for larval proteases.
  154. (1980). Enzyme-linked immunosorbent assay (ELISA) for detecting IgM and IgE antibodies in human schistosomiasis.
  155. (1971). Enzyme-linked immunosorbent assay (ELISA).
  156. (2006). Enzyme-linked immunosorbent assay with worm vomit and cercarial secretions of Schistosoma mansoni to detect infections in an endemic focus of Burkina Faso.
  157. (1991). Eosinophilia and eosinophil helminthotoxicity in patients treated for Schistosoma mansoni infections.
  158. (1994). Epitopes of the Onchocerca volvulus RAL1 antigen, a member of the calreticulin family of proteins, recognized by sera from patients with onchocerciasis.
  159. (1997). Evaluation of a stage-specific proteolytic enzyme of Schistosoma mansoni as a marker of exposure.
  160. (1997). Evaluation of the Kato-Katz thick smear and formol ether sedimentation techniques for quantitative diagnosis of Schistosoma mansoni infection.
  161. (1977). Evidence for adsorption of heterospecific host immunoglobulin on the tegument of Schistosoma mansoni.
  162. (1991). Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels.
  163. (1987). Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice.
  164. (1991). Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni.
  165. (1998). Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation.
  166. (2002). Evolution of the lectin-complement pathway and its role in innate immunity.
  167. (1998). Expresion clonining and characterization of Schistosoma japonicum cDNAs.PhD thesis,
  168. (1993). Expression and partial characterization of a cathepsin Blike enzyme (Sm31) and a proposed 'haemoglobinase' (Sm32) from Schistosoma mansoni.
  169. (1995). Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis.
  170. (1991). Expression of calreticulin in Escherichia coli and identification of its Ca2+ binding domains.
  171. (2002). Expression of calreticulin P-domain results in impairment of secretory pathway in Leishmania donovani and reduced parasite survival in macrophages.
  172. (2005). F(ab')2 antibody fragments against Trypanosoma cruzi calreticulin inhibit its interaction with the first component of human complement.
  173. (1978). Factors affecting the acquisition of resistance against Schistosoma mansoni in the mouse. I. Demonstration of resistance to reinfection using a model system that involves perfusion of mice within three weeks of challenge.
  174. (1991). Factors affecting the intensity of reinfection with Schistosoma haematobium following treatment with praziquantel.
  175. (1979). Factors in the pathogenesis of acute schistosomiasis mansoni.
  176. (1984). Fasciola hepatica and Schistosoma mansoni: immunofluorescent antigen localization and cross-reactivity.
  177. (1992). Fibre-optic sigmoidoscopy compared with the Kato technique in diagnosis and evaluation of the intensity of Schistosoma mansoni infection.
  178. (2000). Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization.
  179. (1996). Fluctuation of schistosome circulating antigen levels in urine of individuals with Schistosoma mansoni infection in Burundi.
  180. (1999). Full results of the genome-wide scan which localises a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33.
  181. (1994). Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59.
  182. (1986). Functional model of subcomponent C1 of human complement.
  183. (1989). Functional role of human IgG subclasses in eosinophil-mediated killing of schistosomula of Schistosoma mansoni.
  184. (2001). Functional specialization of calreticulin domains.
  185. (1997). Further evidence suggesting the presence of a locus, on human chromosome 5q31-q33, influencing the intensity of infection with Schistosoma mansoni.
  186. (1996). Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33.
  187. (2003). Granulomas in schistosome and mycobacterial infections: a model of local immune responses.
  188. (1984). Hatching, chemokinesis, and transformation of miracidia of Schistosoma mansoni.
  189. (1989). Heat shock and the sorting of luminal ER proteins.
  190. (2000). Hepatic schistosomiasis.
  191. (2001). Heterogeneities in anti-schistosome humoral responses following chemotherapy.
  192. (1998). High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni.
  193. (1991). Highly repeated short DNA sequences in the genome of Schistosoma mansoni recognized by a species-specific probe.
  194. (1990). Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase Csensitive surface molecule resembling human decay accelerating factor.
  195. (2001). Human and murine humoral immune recognition of multiple peptides from Schistosoma mansoni glyceraldehyde 3-P dehydrogenase is associated with resistance to Schistosomiasis.
  196. (1988). Human antibody responses against schistosomal antigens. I. Antibodies from patients with Ancylostoma, Ascaris lumbricoides or Schistosoma mansoni infections react with schistosome antigens.
  197. (2006). Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies.
  198. (1988). Human antibody responses to Schistosoma mansoni: the influence of epitopes shared between different life-cycle stages on the response to the schistosomulum.
  199. (1992). Human IgE responses to Schistosoma mansoni and resistance to reinfection. Mem.Inst.Oswaldo Cruz,
  200. (1991). Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium.
  201. (1994). Human IgG subclass responses and subclass restriction to Schistosoma mansoni egg antigens.
  202. (1996). Human immunoglobulin E responses to a recombinant 22.6-kilodalton antigen from Schistosoma mansoni adult worms are associated with low intensities of reinfection after treatment.
  203. (1997). Human schistosomiasis in Puerto Rico: reduced prevalence rate and absence of Biomphalaria glabrata.
  204. (2008). Human schistosomiasis mansoni: immune responses during acute and chronic phases of the infection.
  205. (2001). Human Tand B-cell responses to Schistosoma mansoni recombinant glyceraldehyde 3-phosphate dehydrogenase correlate with resistance to reinfection with S. mansoni or Schistosoma haematobium after chemotherapy.
  206. (1985). Identification and characterization of a major Schistosoma mansoni glycoprotein antigen cross-reactive with Fasciola hepatica.
  207. (1981). Identification and partial purification of an antigen (omega 1) from Schistosoma mansoni eggs which is putatively hepatotoxic in T-cell deprived mice.
  208. (1985). Identification by monoclonal antibody of a major (28 kDa) surface membrane antigen of Schistosoma mansoni.
  209. (1994). Identification of calreticulin as a rubella virus RNA binding protein.
  210. (1986). Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice.
  211. (1995). Identification of the Zn2+ binding region in calreticulin.
  212. (2003). IFN-gamma polymorphisms (IFN-gamma +2109 and IFN-gamma +3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni).
  213. (1993). IgA antibodies to a protective antigen in human Schistosomiasis mansoni.
  214. (2000). IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis.
  215. (2004). IL-13 receptor alpha 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis.
  216. (1988). Immune response in chronic Schistosomiasis haematobium and mansoni. Reversibility of alterations after anti-parasitic treatment with praziquantel.
  217. (1985). Immune responses during human Schistosomiasis mansoni. XI. Immunologic status of patients with acute infections and after treatment.
  218. (1999). Immune responses to the radiation-attenuated schistosome vaccine: what can we learn from knock-out mice?
  219. (1985). Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses.
  220. (1994). Immunity and morbidity in human schistosomiasis mansoni.
  221. (2005). Immunity induced by the radiation-attenuated schistosome vaccine.
  222. (1993). Immunity to Schistosoma mansoni in mice vaccinated with irradiated cercariae: cytokine interactions in the pulmonary protective response.
  223. (1992). Immunity to schistosomes.
  224. (2006). Immunoassays as an auxiliary tool for the serodiagnosis of Schistosoma mansoni infection in individuals with low intensity of egg elimination.
  225. (1999). Immunochemical characterization of Schistosoma mansoni glycolipid antigens.
  226. (2004). Immunocytochemical localisation of calreticulin in Trypanosoma cruzi.
  227. (2000). Immunodiagnosis of schistosomiasis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections.
  228. (1997). Immunodiagnosis of schistosomiasis.
  229. (1994). Immunoglobulin E and effector cells in schistosomiasis.
  230. (2006). Immunoglobulin uptake and processing by Schistosoma mansoni.
  231. (1997). Immunologic basis of disease and disease regulation in schistosomiasis.
  232. (1994). Immunologic characterization of two monoclonal antibodies reactive with repetitive carbohydrate epitopes of circulating Schistosoma mansoni egg antigen.
  233. (1981). Immunological control of hepatotoxicity and parasite egg excretion in Schistosoma mansoni infections: stage specificity of the reactivity of immune serum in T-cell deprived mice.
  234. (1990). Immunological crossreactivity between the human immunodeficiency virus type 1 virion infectivity factor and a 170-kD surface antigen of Schistosoma mansoni.
  235. (1996). Impaired immunity and altered pulmonary responses in mice with a disrupted interferon-gamma receptor gene exposed to the irradiated Schistosoma mansoni vaccine.
  236. (1998). Implications of calreticulin function in parasite biology.
  237. (1990). Implications of faecal egg count variation when using the Kato-Katz method to assess Schistosoma mansoni infections.
  238. (2007). In and out of the ER: protein folding, quality control, degradation, and related human diseases.
  239. (1990). In situ pulmonary responses of T cell and macrophage subpopulations to a challenge infection in mice vaccinated with irradiated cercariae of Schistosoma mansoni.
  240. (1997). In utero exposure to helminth and mycobacterial antigens generates cytokine responses similar to that observed in adults.
  241. (1991). In vitro interaction of a polypeptide homologous to human Ro/SS-A antigen (calreticulin) with a highly conserved Chapter 8 Refrences amino acid sequence in the cytoplasmic domain of integrin alpha subunits.
  242. (2002). In vivo pharmacokinetics of calreticulin S-domain, an inhibitor of the classical complement pathway.
  243. (2006). Increased human IgE induced by killing Schistosoma mansoni in vivo is associated with pretreatment Th2 cytokine responsiveness to worm antigens.
  244. (1998). Inducible nitric oxide synthase-deficient mice develop enhanced type 1 cytokine-associated cellular and humoral immune responses after vaccination with attenuated Schistosoma mansoni cercariae but display partially reduced resistance.
  245. (1985). Induction of immunity in mice to Fasciola hepatica with a Fasciola/Schistosoma cross-reactive defined immunity antigen.
  246. (1988). Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen.
  247. (1992). Induction of protective immunity in mice using a 62-kDa recombinant fragment of a Schistosoma mansoni surface antigen.
  248. (2002). Infection with Schistosoma mansoni correlates with altered immune responses to Ascaris lumbricoides and hookworm.
  249. (2003). Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin.
  250. (1998). Interaction between a Ca2+-binding protein calreticulin and perforin, a component of the cytotoxic T-cell granules.
  251. (1998). Interaction of C1q and the collectins with the potential receptors calreticulin (cC1qR/collectin receptor) and megalin.
  252. (1995). Interaction of calreticulin with protein disulfide isomerase.
  253. (1997). Interactions between newly synthesized glycoproteins, calnexin and a network of resident chaperones in the endoplasmic reticulum.
  254. (1995). Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture.
  255. (1994). Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis.
  256. (2005). Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections.
  257. (1995). Interleukin-6 production by human liver (myo)fibroblasts in culture. Evidence for a regulatory role of LPS, IL-1 beta and TNF alpha.
  258. (2002). Invasion of skin by Schistosoma cercariae.
  259. (2004). Involvement of central nervous system in the schistosomiasis.
  260. (1998). Is IgG2a a good Th1 marker in mice?
  261. (1998). Is Schistosomicidal Chemotherapy Sub-curative? Implications for Drug Resistance.
  262. (1996). Isolation and characterization of Leishmania donovani calreticulin gene and its conservation of the RNA binding activity.
  263. (1974). Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum.
  264. (2007). Katayama syndrome.
  265. (1996). Kinetics and mechanism of effector focus formation in the lungs of mice vaccinated with irradiated cercariae of Schistosoma mansoni.
  266. (2004). Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis.
  267. (1991). Levels of the schistosome circulating anodic and cathodic antigens in serum of schistosomiasis patients from Brazil.
  268. (1996). Localisation of the C1q binding site within C1q receptor/calreticulin.
  269. (1988). Longitudinal studies on human schistosomiasis.
  270. (1982). Loss of covalently labeled glycoproteins and glycolipids from the surface of newly transformed schistosomula of Schistosoma mansoni.
  271. (1991). Low density lipoproteins bound to Schistosoma mansoni do not alter the rapid lateral diffusion or shedding of lipids in the outer surface membrane.
  272. (1992). Magnetic bead antigen capture enzyme-linked immunoassay in microtitre trays for rapid detection of schistosomal circulating anodic antigen.
  273. (2007). Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
  274. (2009). Mapping the complement C1q binding site in Haemonchus contortus calreticulin.
  275. (2005). Mass spectrometric analysis of the Schistosoma mansoni tegumental sub-proteome.
  276. (2008). Mass spectrometric detection of urinary oligosaccharides as markers of Schistosoma mansoni infection.
  277. (1995). Measurement of antibody response to keyhole limpet haemocyanin was not adequate for early diagnosis of schistosomiasis in a group of Dutch visitors to Mali.
  278. (1978). Method of hatching miracidia for the diagnosis of schistosomiasis mansoni in epidemiological surveys.
  279. (2000). Migration and urban schistosomiasis. The case of Sao Lourenco da Mata, northeast of Brazil.
  280. (1988). Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta.
  281. (2006). Molecular approaches for the detection of Schistosoma mansoni: possible applications in the detection of snail infection, monitoring of transmission sites, and diagnosis of human infection. Mem.Inst.Oswaldo Cruz,
  282. (1991). Molecular characterization of the Ro/SS-A autoimmune response.
  283. (1987). Molecular cloning of a protective antigen of schistosomes.
  284. (1989). Molecular cloning of the high affinity calcium-binding protein (calreticulin) of skeletal muscle sarcoplasmic reticulum.
  285. (1986). Molecular identity of a major antigen of Schistosoma mansoni which cross-reacts with Trichinella spiralis and Fasciola hepatica.
  286. (1994). Monitoring the efficacy of different doses of praziquantel by quantification of circulating antigens in serum and urine of schistosomiasis patients.
  287. (1998). Morbidity in schistosomiasis: assessment, mechanisms and control.
  288. (1989). Multiple zones in the sequence of calreticulin (CRP55, calregulin, HACBP), a major calcium binding ER/SR protein.
  289. (2008). Multiplex real-time PCR for the detection and quantification of Schistosoma mansoni and S. haematobium infection in stool samples collected in northern Senegal.
  290. (2000). Natural versus drug-induced resistance in Schistosoma mansoni infection.
  291. (1999). Neonatal exposure to idiotype induces Schistosoma mansoni egg antigen-specific cellular and humoral immune responses.
  292. (1992). New approaches for the control and eradication of schistosomiasis in Venezuela. Mem.Inst.Oswaldo Cruz,
  293. (1995). Novel mechanisms of immune evasion by Schistosoma mansoni.
  294. (1994). Nuclear Ca2+: physiological regulation and role in apoptosis.
  295. (1998). Oligosaccharide binding characteristics of the molecular chaperones calnexin and calreticulin.
  296. (1992). On the use of ageintensity data to detect immunity to parasitic infections, with special reference to Schistosoma mansoni in Kenya.
  297. (1999). Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFN-gamma-dependent effector mechanisms.
  298. (2000). Oral fluids for the immunodiagnosis of Schistosoma mansoni infection.
  299. (1995). Outbreak of schistosomiasis among travelers returning from Mali, West Africa.
  300. (1995). Overexpression of calreticulin increases the Ca2+ capacity of rapidly exchanging Ca2+ stores and reveals aspects of their lumenal microenvironment and function.
  301. (1992). Paramyosin inhibits complement C1.
  302. (1991). Paramyosin is the Schistosoma mansoni (Trematoda) homologue of antigen B from Taenia solium (Cestoda).
  303. (1996). Paramyosin isoforms of Schistosoma mansoni are phosphorylated and localized in a large variety of muscle types.
  304. (2009). Penetration of cercariae into the living human skin: Schistosoma mansoni vs. Trichobilharzia szidati.
  305. (2000). Perforin lytic activity is controlled by calreticulin.
  306. (1999). Periodate-sensitive immunological cross-reactivity between keyhole limpet haemocyanin (KLH) and serodiagnostic Schistosoma mansoni egg antigens.
  307. (2003). Pivotal roles of the parasite PGD2 synthase and of the host D prostanoid receptor 1 in schistosome immune evasion.
  308. (1996). Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen-specific IgE.
  309. (2000). Praziquantel and the control of schistosomiasis.
  310. (1999). Praziquantel--its use, cost and possible development of resistance.
  311. (1996). Presence of calreticulin in vector fleas (Siphonaptera).
  312. (1989). Presence of the schistosome circulating anodic antigen (CAA) in urine of patients with Schistosoma mansoni or S. haematobium infections.
  313. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a nonendemic country.
  314. (2002). Prevention and control of schistosomiasis and soil-tarnsmitted helminthiasis: Report of a WHO expert committee.
  315. (2004). Progress in the prevention and control of schistosomiasis and soil-transmitted helminthiasis.
  316. (1988). Properties of serine proteases of Schistosoma mansoni schistosomula involved in the regulation of IgE synthesis.
  317. (1997). Protection against Schistosoma mansoni infection with a recombinant baculovirusexpressed subunit of calpain.
  318. (1993). Protective immunity in baboons vaccinated with a recombinant antigen or radiation-attenuated cercariae of Schistosoma mansoni is antibody-dependent.
  319. (2006). Proteins exposed at the adult schistosome surface revealed by biotinylation.
  320. (1997). Proteolytic degradation of host hemoglobin by schistosomes.
  321. Pubertal development predicts resistance to infection and reinfection with Schistosoma japonicum.
  322. (1998). Puberty and Age-related Changes in Susceptibility to Schistosome Infection.
  323. (2000). Purification and biochemical characterization of three cysteine proteases of Entamoeba histolytica with potential application in epidemiologic trials.
  324. (1988). Purification and immunochemical characterization of a 22 kilodalton surface antigen from Schistosoma mansoni.
  325. (1995). Purification and preliminary sequencing of Tc-45, an immunodominant Trypanosoma cruzi antigen: absence of homology with cruzipain, cruzain, and a 46-kilodalton protein.
  326. (2003). Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa.
  327. (1989). Quantitative determination of circulating antigens in human schistosomiasis mansoni using an indirect hemagglutination assay.
  328. (1994). Quantitative determination of circulating soluble egg antigen in urine and serum of Schistosoma mansoni-infected individuals using a combined two-site enzyme-linked immunosorbent assay.
  329. (1994). Quantitative diagnosis of Schistosoma infections by measurement of circulating antigens in serum and urine.
  330. (1994). Rapid diagnosis of schistosomiasis by antigen detection in urine with a reagent strip.
  331. (2005). Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis.
  332. (2002). Recent advances in the diagnosis of Schistosoma infection: the detection of parasite DNA.
  333. (2001). Receptor for Fc on the surfaces of schistosomes.
  334. (1997). Recognition of an immunogenetically selected Trypanosoma cruzi antigen by seropositive chagasic human sera.
  335. (1991). Regulation and biological function of helminth-induced cytokine responses.
  336. (1991). Regulation of expression and intracellular distribution of calreticulin, a major calcium binding protein of nonmuscle cells.
  337. (2006). Regulation of peripheral T cell activation by calreticulin.
  338. (1997). Release of calreticulin from neutrophils may alter C1q-mediated immune functions.
  339. (2001). Report of the Informed Consultation on Schistosomiasis
  340. (1999). Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.
  341. Resistance to Schistosoma mansoni in humans: influence of the IgE/IgG4 balance and IgG2 in immunity to reinfection after chemotherapy.
  342. (2004). Role of calreticulin from parasites in its interaction with vertebrate hosts.
  343. (1991). Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro.
  344. (2001). Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection.
  345. (1993). Schistosoma mansoni 28-kDa glutathione S-transferase and immunity against parasite fecundity and egg viability. Role of the aminoand carboxyl-terminal domains.
  346. Schistosoma mansoni adult microsomal antigens, a serologic reagent. II. Specificity of antibody responses to the S. mansoni microsomal antigen (MAMA).
  347. (1991). Schistosoma mansoni and S. japonicum: decline of antibodies against diagnostic adult worm antigens (Sm31/32) following praziquantel treatment of mice.
  348. (1988). Schistosoma mansoni cationic egg antigens (CEF6): immunoserology with oxamniquine-treated patients and involvement of CEF6 in the circumoval precipitin reaction.
  349. (1997). Schistosoma mansoni cercariae: stimulation of acetabular gland secretion is adapted to the chemical composition of mammalian skin.
  350. (1993). Schistosoma mansoni circulating anodic antigen but not circulating cathodic antigen interacts with complement component C1q.
  351. (1983). Schistosoma mansoni egg antigens and hepatocyte damage in infected T cell-deprived mice.
  352. (2007). Schistosoma mansoni eggs excrete specific free oligosaccharides that are detectable in the urine of the human host.
  353. (1987). Schistosoma mansoni shares a protective carbohydrate epitope with keyhole limpet hemocyanin.
  354. (2008). Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection.
  355. (2008). Schistosoma mansoni triose phosphate isomerase peptide MAP4 is able to trigger naive donor immune response towards a type-1 cytokine profile.
  356. (2000). Schistosoma mansoni: adhesion of mannan-binding lectin to surface glycoproteins of cercariae and adult worms.
  357. (1992). Schistosoma mansoni: cell-specific expression and secretion of a serine protease during development of cercariae.
  358. (1974). Schistosoma mansoni: cercaria to schistosomule.
  359. (1991). Schistosoma mansoni: characterization and identification of calcium-binding proteins associated with the apical plasma membrane and envelope.
  360. (1996). Schistosoma mansoni: evidence for a 28-kDa membrane-anchored protease on schistosomula.
  361. (1991). Schistosoma mansoni: immunolocalization of the calcium binding protein Sm20. Parasite Immunol.,
  362. (1993). Schistosoma mansoni: immunoreactivity of human sera with the surface antigen Sm23.
  363. (1987). Schistosoma mansoni: interactions of adult parasites with the complement system.
  364. (1994). Schistosoma mansoni: isolation and characterization of Smpi56, a novel serine protease inhibitor.
  365. (1986). Schistosoma mansoni: killing of transformed schistosomula by the alternative pathway of human complement.
  366. (1974). Schistosoma mansoni: simplified method for the production of schistosomules.
  367. (1997). Schistosoma mansoni: susceptibility differences between male and female mice can be mediated by testosterone during early infection.
  368. (1978). Schistosoma mansoni: the activity and development of the schistosomulum during migration from the skin to the hepatic portal system.
  369. (1999). Schistosoma TOR (trispanning orphan receptor), a novel, antigenic surface receptor of the blood-dwelling, Schistosoma parasite.
  370. (1998). Schistosome immunology: more questions than answers.
  371. (2007). Schistosome membrane proteins as vaccines.
  372. (2006). Schistosome vaccines: a critical appraisal. Mem.Inst.Oswaldo Cruz,
  373. (2004). Schistosomes in the skin: a balance between immune priming and regulation.
  374. (2005). Schistosomes: the road from host-parasite interactions to vaccines in clinical trials.
  375. (2001). Schistosomiasis epidemiology and control: how did we get here and where should we go? Mem.Inst.Oswaldo Cruz, 96 Suppl,
  376. (2001). Schistosomiasis in the People's Republic of China: prospects and challenges for the 21st century.
  377. (1997). Schistosomiasis vaccine development--the current picture.
  378. (1995). Schistosomiasis vaccine development: approaches and prospects.
  379. (1998). Schistosomiasis vaccine:research to development.
  380. (2002). Schistosomiasis: from risk assessment to control.
  381. (1996). Schistosomiasis. Pathophysiology, diagnosis, and treatment.
  382. (1989). Sensitive determination of circulating anodic antigen in Schistosoma mansoni infected individuals by an enzyme-linked immunosorbent assay using monoclonal antibodies.
  383. (1987). Sera of Schistosoma japonicuminfected patients cross-react with diagnostic 31/32 kD proteins of S.
  384. (1991). sera of schistosomiasis patients.
  385. (1981). Serodiagnosis of human Schistosoma mansoni infections: enhanced sensitivity and specificity in ELISA using a fraction containing S. mansoni egg antigens omega 1 and alpha 1.
  386. (2002). Serodiagnosis of imported schistosomiasis by a combination of a commercial indirect hemagglutination test with Schistosoma mansoni adult worm antigens and an enzymelinked immunosorbent assay with S. mansoni egg antigens.
  387. (1985). Serodiagnosis of mansonian schistosomiasis with CEF6, a cationic antigen fraction of Schistosoma mansoni eggs.
  388. (1993). Seroepidemiology and serodiagnosis of schistosomiasis in Kenya using crude and purified egg antigens of Schistosoma mansoni in ELISA.
  389. (1992). Seroepidemiology of schistosomiasis mansoni.
  390. (1992). Serological cross-reactivity between a human Ro/SS-A autoantigen (calreticulin) and the lambda Ral-1 antigen of Onchocerca volvulus.
  391. (1979). Serological differences between acute and chronic schistosomiasis mansoni detected by enzyme-linked immunosorbent assay (ELISA).
  392. (2003). Serological differentiation of acute and chronic schistosomiasis using Schistosoma mansoni recombinant protein RP26.
  393. (2004). Serological speciation of human schistosome infections by ELISA with a panel of three antigens.
  394. (1989). Serology of Schistosoma mansoni infections after chemotherapy.
  395. (1998). Serum circulating egg antigen levels in two areas endemic for Schistosoma mansoni.
  396. (1999). Setting the standards: quality control in the secretory pathway.
  397. (2002). Sm14 gene expression in different stages of the Schistosoma mansoni life cycle and immunolocalization of the Sm14 protein within the adult worm.
  398. (2004). Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice.
  399. (2004). Specific and sensitive diagnosis of schistosome infection: can it be done with antibodies?
  400. (2003). Specific antibody responses to three schistosomerelated carbohydrate structures in recently exposed immigrants and established residents in an area of Schistosoma mansoni endemicity.
  401. (1991). Specific IgG activity of sera from Egyptian schistosomiasis patients to keyhole limpet hemocyanin (KLH).
  402. (2000). Specificity of circulating antigen detection for schistosomiasis mansoni in Senegal and Burundi.
  403. (1998). Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance.
  404. (1983). Staining of the Ca2+-binding proteins, calsequestrin, calmodulin, troponin C, and S-100, with the cationic carbocyanine dye "Stains-all".
  405. (1992). Stool examination and rectal biopsy in the diagnosis and evaluation of therapy of schistosomiasis mansoni.
  406. (1992). Strong serum inhibition of specific IgE correlated to competing IgG4, revealed by a new methodology in subjects from a S. mansoni endemic area.
  407. (1999). Studies on phospholipid turnover argue against sloughing of tegumental membranes in adult Schistosoma mansoni.
  408. (1997). Studies on schistosomiasis in western Kenya: I. Evidence for immune-facilitated excretion of schistosome eggs from patients with Schistosoma mansoni and human immunodeficiency virus coinfections.
  409. (1978). Studies on the enzyme linked immunosorbent assay (ELISA) test for Schistosoma mansoni infections.
  410. (2005). Surface calreticulin mediates muramyl dipeptide-induced apoptosis in RK13 cells.
  411. (2008). Swimming behaviour of Schistosoma mansoni cercariae: responses to irradiance changes and skin attractants.
  412. (1992). T and B cell epitope mapping of SM23, an integral membrane protein of Schistosoma mansoni.
  413. (1994). T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase.
  414. (1990). T cell clones for antigen selection and lymphokine production in murine Schistosomiasis mansoni.
  415. T cell-derived cytokines associated with pulmonary immune mechanisms in mice vaccinated with irradiated cercariae of Schistosoma mansoni.
  416. (2007). Targeted identification of a unique glycan epitope of Schistosoma mansoni egg antigens using a diagnostic antibody.
  417. (2000). Tc45, a dimorphic Trypanosoma cruzi immunogen with variable chromosomal localization, is calreticulin.
  418. (2010). tegument and induces partial protection against challenge infection.
  419. (1980). Tegument-associated antigen modulation by adult male Schistosoma mansoni.
  420. (2006). Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis.
  421. (1998). Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response.
  422. (2001). The 14-3-3 protein as a vaccine candidate against schistosomiasis.
  423. (1948). The action of miracil in Schistosoma japonicum infections in laboratory animals.
  424. (1989). The application of S. mansoni adult and soluble egg antigens for the serodiagnosis of schistosomiasis by CIEP,
  425. (2005). The assessment of hookworm calreticulin as a potential vaccine for necatoriasis.
  426. (1982). The biology and toxicology of molluscicides,
  427. (1997). The C1q and collectin binding site within C1q receptor (cell surface calreticulin).
  428. (1993). The calcium-binding protein calreticulin is a major constituent of lytic granules in cytolytic T lymphocytes.
  429. (1974). The characteristics of a circulating antigen in schistosomiasis.
  430. (2000). The conformation of calreticulin is influenced by the endoplasmic reticulum luminal environment.
  431. (2003). The contribution of N-glycans and their processing in the endoplasmic reticulum to glycoprotein biosynthesis.
  432. (1993). The control of
  433. (1976). The detection of viruses by enzyme-linked immunosorbent assay (ELISA).
  434. (1987). The diagnosis and treatment of acute toxaemic schistosomiasis in children.
  435. (1998). The distribution of Schistosoma japonicum eggs in faeces and the effect of stirring faecal specimens.
  436. (1998). The dynamics of a soluble egg antigen of Schistosoma haematobium in relation to egg counts, circulating anodic and cathodic antigens and pathology markers before and after chemotherapy.
  437. (2002). The effects of immunization with recombinant Sm14 (rSm14) in reducing worm burden and mortality of mice infected with Schistosoma mansoni.
  438. (2008). The endoplasmic reticulum chaperone calreticulin is recruited to the uropod during capping of surface receptors in Entamoeba histolytica.
  439. (1992). The generation of interferon-gamma-producing T lymphocytes in skin-draining lymph nodes, and their recruitment to the lungs, is associated with protective immunity to Schistosoma mansoni.
  440. (2002). The global epidemiological situation of schistosomiasis and new approaches to control and research.
  441. (2000). The global status of schistosomiasis and its control.
  442. (1988). The glutathione transferase activity and tissue distribution of a cloned Mr28K protective antigen of Schistosoma mansoni.
  443. (1989). The human immune response to defined immunogens of Schistosoma mansoni: elevated antibody levels to paramyosin in stoolnegative individuals from two endemic areas in Brazil.
  444. (1990). The humoral response to heat shock protein 70 in human and murine Schistosomiasis mansoni.
  445. (2004). The immunobiology of Th1 polarization in high-pathology schistosomiasis.
  446. (1994). The immunologically reactive part of immunopurified circulating anodic antigen from Schistosoma mansoni is a threonine-linked polysaccharide consisting of --> 6)-(beta-D-GlcpA-(1 --> 3))-beta-D-GalpNAc-(1 --> repeating units.
  447. (2006). The impact of two education methods on knowledge of schistosomiasis transmission and prevention among schoolchildren in a rural community in northern Minas Gerais, Brazil. Mem.Inst.Oswaldo Cruz,
  448. (1997). The incorporation, modification and turnover of fatty acids in adult Schistosoma mansoni.
  449. (1965). The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms.
  450. (1968). The inhibition of granuloma formation around Schistosoma mansoni eggs. 3. Heterologous antilymphocyte serum.
  451. (1995). the initial phase of schistosomiasis mansoni.
  452. (2001). The ins and outs of calreticulin: from the ER lumen to the extracellular space.
  453. (2002). The mannanbinding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes.
  454. (1995). The mitogenic effects of the B beta chain of fibrinogen are mediated through cell surface calreticulin.
  455. (1988). The morbidity of schistosomiasis mansoni in the Rusizi Plain (Burundi).
  456. (1991). The purification, characterization, serological activity and hepatotoxic properties of two cationic glycoproteins (alpha 1 and omega 1) from Schistosoma mansoni eggs.
  457. (1999). The regulatory role of the antigen-presenting cell in the development of hepatic immunopathology during infection with Schistosoma mansoni.
  458. (1995). The relationship between worm burden and levels of a circulating antigen (CAA) of five species of Schistosoma in mice.
  459. (1986). The schistosome egg granuloma: immunopathology in the cause of host protection or parasite survival?
  460. (1996). The serological differentiation of acute and chronic schistosomiasis japonica using IgA antibody to egg antigen.
  461. (1984). The stage-, strain- and species-specificity of a Schistosoma mansoni egg antigen fraction (CEF6) with serodiagnostic potential.
  462. (2006). The tegument surface membranes of the human blood parasite Schistosoma mansoni: a proteomic analysis after differential extraction.
  463. (2001). The unreliability of the KatoKatz technique limits its usefulness for evaluating S. mansoni infections.
  464. (2001). Three-dimensional structure topology of the calreticulin P-domain based on NMR assignment.
  465. (1999). TNF is essential for the cell-mediated protective immunity induced by the radiation-attenuated schistosome vaccine.
  466. (1999). Tolerization of mice to Schistosoma mansoni egg antigens causes elevated type 1 and diminished type 2 cytokine responses and increased mortality in acute infection.
  467. (2003). Topical application of DEET for schistosomiasis.
  468. (2007). Touchdown PCR, ELISA and stool examination for early diagnosing of Schistosoma mansoni in mice.
  469. (2009). Toward the elimination of schistosomiasis.
  470. (2003). Treatment and re-treatment strategies for schistosomiasis control in different epidemiological settings: a review of 10 years' experiences.
  471. Two new field techniques for detection and counting of Schistosoma haematobium eggs in urine samples, with an evaluation of both methods.
  472. (2007). two parasites of Biomphalaria glabrata.
  473. (1996). Uncertainties in the epidemiology and control of schistosomiasis.
  474. (1992). Underestimation of Schistosoma mansoni prevalences.
  475. (1986). Unusual ultrastructure of complementcomponent-C4b-binding protein of human complement by synchrotron X-ray scattering and hydrodynamic analysis.
  476. (2002). Upgrading of Kato-Katz technique for diagnosis of S. mansoni infection in rural Egypt.
  477. (1998). Use of monoclonal antibodies prepared against Schistosoma mansoni hatching fluid antigens for demonstration of Schistosoma haematobium circulating egg antigens in urine.
  478. (2001). Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum.
  479. (2005). Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol.,
  480. (1997). Variation in weight of stool samples prepared by the Kato-Katz method and its implications.
  481. (2004). Variations in helminth faecal egg counts in Kato-Katz thick smears and their implications in assessing infection status with Schistosoma mansoni.
  482. (1996). Water contact observations in Kenyan communities endemic for schistosomiasis: methodology and patterns of behaviour.
  483. (1998). Why don't we have a schistosomiasis vaccine?
  484. (1996). Worm burdens in schistosome infections.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.